tbuckley/cabot-search huggingface dataset:
THE BACTERIOLOGY OF SYPHILIS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study
Authors: A. L. Stewart
Journal: JAMA (1989)

Enhancing daily functioning and well-being is an increasingly advocated goal in the treatment of patients with chronic conditions. We evaluated the functioning and well-being of 9385 adults at the time of office visits to 362 physicians in three US cities, using brief surveys completed by both patients and physicians. For eight of nine common chronic medical conditions, patients with the condition showed markedly worse physical, role, and social functioning; mental health; health perceptions; and/or bodily pain compared with patients with no chronic conditions. Each condition had a unique profile among the various health components. Hypertension had the least overall impact; heart disease and patient-reported gastrointestinal disorders had the greatest impact. Patients with multiple conditions showed greater decrements in functioning and well-being than those with only one condition. Substantial variations in functioning and well-being within each chronic condition group remain to be explained. (<i>JAMA</i>. 1989;262:907-913)
Family Psychotherapy
Authors: F. Knobloch
Journal: Psychotherapy and Psychosomatics (1965)

Case Reports| February 11 2010 Family Psychotherapy Subject Area: Psychiatry and Psychology F. Knobloch F. Knobloch Psychiatric Department of the University Policlinic, Charles University, Prague and the Rehabilitation Neurosis Centre, Lobec Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1965) 13 (1-3): 155–163. https://doi.org/10.1159/000285765 Article history Published Online: February 11 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation F. Knobloch; Family Psychotherapy. Psychother Psychosom 31 December 1965; 13 (1-3): 155–163. https://doi.org/10.1159/000285765 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1965Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Medical Ophthalmology.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cognitive dysfunction in cancer patients likely not all due to chemotherapy
Authors: Kerstin Hermelink, Daniel Luzer
Journal: JNCI Journal of the National Cancer Institute (2017)

Cognitive dysfunction in cancer patients likely not all due to chemotherapyA new study published in the Journal of the National C'ancer Institute indicates that, while breast cancer patients may encounter subtle cognitive dysfunction, most of this appears to be mediated by cancer-related post-traumatic stress disorder (PTSD), and the cognitive dysfunction occurs largely irrespective of chemotherapy.Cancer-related cognitive dysfunction has mostly been attributed to chemotherapy; this explanation, however, fails to account for cognitive dysfunction observed in cancer patients who do not receive chemotherapy.In a controlled, longitudinal, study researchers tested the hypothesis that cognitive function in breast cancer patients is affected by cancer-related post-traumatic stress.Many patients with breast or other non-nervous system cancers report cognitive dysfunction and some are considerably burdened by it.The role of chemotherapy neurotoxicity for cognitive dysfunction in cancer patients, however, has been questioned by findings of cognitive dysfunction in patients whose treatment had not yet begun or who were managed without chemotherapy.Recent investigations have linked pretreatment cognitive impairment to inflammatory processes caused by the tumor itself.
Beware, the Sporothrix
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2796: Validation of Brightplex, a multiplexed IHC solution for immune cell phenotyping of the tumor microenvironment
Authors: Aurélie Collignon, Assil Benchaaben, Alboukadel Kassambara, Felipe Guimaraes, Emmanuel Prestat, Christophe Haond, Jacques Fieschi
Journal: Cancer Research (2019)

Abstract Brightplex is a multiplexing solution developed by HalioDx to analyze the tumor microenvironment on FFPE tissue. It leverages chromogenic immunohistochemistry performed by iterative automated immunostaining on the same slide followed by whole slide digital pathology analysis based on proprietary software combined to Halo from Indica Lab. Stained cells can be quantified in various regions of interest (tumor, stroma, invasion margin). The Brightplex T cell exhaustion (TCE) panel includes 5 biomarkers (CD3, CD8, PD1, TIM3 and LAG3) to assess the expression of three immune checkpoints on T cells. This panel is intended to be used in clinical research to identify patients susceptible to respond to new immunotherapies especially in the context of the resistance to anti PD(L)1 treatment. Therefore, it is critical to thoroughly demonstrate the robustness and the accuracy of such complex assay. For the validation study of the TCE panel, tissue sections were sequentially immunostained for TIM3, PD1, LAG3, CD8 and CD3. Following each immunostaining, the slides were digitized, de-stained and the antibodies stripped before the next immunostaining. Images of the whole slide were then coregistered and analyzed by digital pathology to determine the densities of various T cell populations: CD8+ T lymphocytes expressing of 1, 2 or 3 immune checkpoints. The precision of the assay was evaluated in terms of intra- and inter-run repeatability and the accuracy was evaluated by comparison of the automated multiplex assay with singleplex staining. Results demonstrate the reliability of Brightplex to analyze tumor sections. The precision study showed that Brightplex was reproductible on several tumor types such as NSCLC, colon and breast and the accuracy was demonstrated by comparison of cell density for each biomarker following either multiplex or singleplex staining. The high degree of robustness could be explained notably by the iterative chromogenic immunohistochemistry technology which limits the risks of steric hindrance when antibodies and amplification systems are used simultaneously and by the intrinsic robustness of this routine workflow including IVD grade instrument and reagents. Citation Format: Aurélie Collignon, Assil Benchaaben, Alboukadel Kassambara, Felipe Guimaraes, Emmanuel Prestat, Christophe Haond, Jacques Fieschi. Validation of Brightplex, a multiplexed IHC solution for immune cell phenotyping of the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2796.
Neonatal subclinical adrenal insufficiency. Result of maternal steroid therapy
Authors: L. A. Grajwer
Journal: JAMA (1977)

STEROID-INDUCED diabetes and greatly reduced urinary estriol levels developed in a pregnant woman with pseudotumor cerebri. The infant was born with subclinical adrenal insufficiency. <h3>Report of a Case</h3> A 19-year-old woman was examined at 10 weeks of gestation, with headaches, vomiting, and photophobia. Physical examination showed a 77 kg, 1.70 m normotensive woman. Eye findings included papilledema, slightly constricted visual fields, and enlarged blind spots bilaterally. A lumbar puncture showed an opening pressure greater than 590 mm of water. Skull roentgenogram, electroencephalogram, and echoencephalogram results were normal. Corticoid levels, measured by a modified fluorometric determination, were 25 μg/dl at 8:00 AM and 12 μg/dl at 4:00 PM. Diagnosis of benign intracranial hypertension was made and glycerol therapy was started. Symptoms abated, only to reappear a week later. After the results of her glucose tolerance test (GTT) were found to be normal, she was treated with dexamethasone, 4 mg every 6
Section Discussions
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poster Discussions
Authors: M. M. Berger, M. J. Reymond, A. Shenkin, C. A. Wardle, F. Rey, A. Pannatier, C. Cavadini, R. C. Gaillard, R. Chloléro, C. D. Spies, H. Rommelspacher, A. Ehlert, W. Schaffartzik, A. A. -B. Badawy, P. V. Carroll, N. C. Jackson, M. Umpleby, P. H. Sönksen, D. L. Russell-Jones, D. F. Treacher, A. Brinkmann, C. -F. Wolf, E. Kneitinger, P. Radermacher, W. Seeling, M. Georgieff, H. Ensinger, A. Rantala, J. Vogt, J. Takala
Journal: Intensive Care Medicine (1996)
Application of Biologic Markers to Studies of Environmental Risks in Children and the Developing Fetus
Authors: Robin M. Whyatt, Frederica P. Perera
Journal: Environmental Health Perspectives (1995)

Young children and the developing fetus may be more susceptible to effects of environmental toxicants than adults due to differential exposure patterns and developmental immaturities.Biologic markers offer the potential of quantitative dosimeters of biologic dose and/or indices of biologic effect associated with fetal/childhood exposures.They can facilitate evaluation of interindividual variability in response and the magnitude of age- related susceptibilities.Thus far, biologic markers have not been widely used in developmental epidemiology of environmental exposures.Research by our group and others has seen elevations in biologic markers in samples from children and fetal tissue associated with a spectrum of environ- mental exposures, including tobacco smoke (active and passive), ambient pollution, and dietary contaminants.Studies also suggest that biologic markers can provide powerful dosimeters for investigating reproductive effects.Validation of biologic markers offering the greatest promise for developmental epidemiology is needed.
Self-Assessment examination of the American Academy of Dermatology * *Members of the Self-Assessment Committee of the American Academy of Dermatology are Mary Ruth Buchness, MD, chairman, Michael J. Adler, MD (resident), Ponciano D. Cruz, Jr., MD, Dorothy Cunningham, MD, Rebecca Giles, MD, Abigail L. Haberman, MD, Thomas Helm, MD, Francisco A. Kerdel, MD, Paul A. Krusinski, MD, Andrew P. Lazar, MD, Clark C. Otley, MD, Mary Spellman, MD, Mary S. Stone, MD, and Allison Vidimos, MD.
Journal: Journal of the American Academy of Dermatology (1997)
Letter from the Editorial Team
Authors: The Editorial Team
Journal: British Journal of Dermatology (2002)

On June 1st, 2002, the British Journal of Dermatology is Ôgoing liveÕ with Manuscript Central.This is an Internet-based system currently used by over 130 international journals, where authors submit and resubmit articles on line, and are able to watch the progression of their manuscripts through the peer review process.Submitting papers in this way is much easier and quicker, involving far less paper and avoiding postal delays.The peer review process will also occur directly through e-mail and the Internet, and we are anticipating a time reduction in this area in particular.
Laryngeal coccidioidomycosis
Authors: M. A. Platt
Journal: JAMA (1977)

A patient had severe bilateral pulmonary coccidioidomycosis with laryngeal involvement proved on biopsy to be caused by<i>Coccidioides immitis</i>. To my knowledge, this has been reported only once before and appears to be a rarely seen complication of pulmonary infection caused by direct inoculation. (<i>JAMA</i>237:1234-1235, 1977)
The Lettsomian Lectures on some Clinical Aspects of Granular Kidney: Delivered before the Medical Society of London
Authors: S. West
Journal: BMJ (1899)

i. Filtlhy habits of the people, such as spitting over the floor and others mentioned above.2. Filthy houses.3. Overcrowding, and consequent rapid increase of con- tagious disease when once imported.4. Presence of rats, insects, and other vermin.5. The naked condition of the people going about, such people presenting almost unlimited opportunities for the entrance into their tissues of plague poison by inoculation and through abrasions.6. Pollution of soil and houses with the excretions of man and animals.7. Filthy clotlling anid absence of bodily lhygiene.DIiPHTHERIA.
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study
Journal: BMJ (2011)

Objectives To determine the accuracy and acceptability to patients of non-endoscopic screening for Barrett's oesophagus, using an ingestible oesophageal sampling device (Cytosponge) coupled with immunocytochemisty for trefoil factor 3. Design Prospective cohort study.Setting 12 UK general practices, with gastroscopies carried out in one hospital endoscopy unit.Participants 504 of 2696 eligible patients (18.7%) aged 50 to 70 years with a previous prescription for an acid suppressant (H 2 receptor antagonist or proton pump inhibitor) for more than three months in the past five years.Main outcome measures Sensitivity and specificity estimates for detecting Barrett's oesophagus compared with gastroscopy as the ideal method, and patient anxiety (short form Spielberger state trait anxiety inventory, impact of events scale) and acceptability (visual analogue scale) of the test.Results 501 of 504 (99%) participants (median age 62, male to female ratio 1:1.2) successfully swallowed the Cytosponge.No serious adverse events occurred.In total, 3.0% (15/501) had an endoscopic diagnosis of Barrett's oesophagus (≥1 cm circumferential length, median circumferential and maximal length of 2 cm and 5 cm, respectively) with intestinal metaplasia.Compared with gastroscopy the sensitivity and specificity of the test was 73.3% (95% confidence interval 44.9% to 92.2%) and 93.8% (91.3% to 95.8%) for 1 cm or more circumferential length and 90.0%(55.5% to 99.7%) and 93.5% (90.9% to 95.5%) for clinically relevant segments of 2 cm or more.Most participants (355/496, 82%, 95% confidence interval 78.9% to 85.1%) reported low levels of anxiety before the test, and scores remained within normal limits at follow-up.Less than 4.5% (2.8% to 6.1%) of participants reported psychological distress a week after the procedure. ConclusionsThe performance of the Cytosponge test was promising and the procedure was well tolerated.These data bring screening for Barrett's oesophagus into the realm of possibility.Further evaluation is recommended.
Geriatrics—The Care of the Aged
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antilymphocyte antisera in immunologically mediated renal disease
Authors: B. Pirofsky
Journal: JAMA (1969)

Antilymphocyte and antithymocyte antisera were produced in goats and used to treat three patients with severe renal disease. Two subjects had progressive lupus erythematosus nephropathy and one patient had Goodpasture's syndrome. Corticosteroid and azathioprine therapy had failed in all. Prompt remissions were initiated in two of the three patients. No untoward local or systemic reactions were encountered. Goat rather than equine antisera appear to offer distinct advantages for such therapy.
ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages
Authors: Andreas W. Jehle, Shyra J. Gardai, Suzhao Li, Patrick Linsel-Nitschke, Konosuke Morimoto, William J. Janssen, R. William Vandivier, Nan Wang, Steven Greenberg, Benjamin M. Dale, Chunbo Qin, Peter M. Henson, Alan R. Tall
Journal: The Journal of Experimental Medicine (2006)